`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE EASTERN DISTRICT OF TEXAS
`MARSHALL DIVISION
`
`SEAGEN INC.,
`
`
`Plaintiff,
`
`
`
`v.
`
`
`DAIICHI SANKYO CO., LTD.,
`
`
`Defendant, and
`
`
`ASTRAZENECA PHARMACEUTICALS
`LP and ASTRAZENECA UK LTD.,
`
`
`Intervenor-Defendants.
`
`
`
`
`
`CASE NO. 2:20-cv-00337-JRG
`
`
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`
`
`
`DEFENDANTS’ RESPONSE TO SEAGEN’S NOTICE OF RIPENESS
`ON MOTION FOR ENTRY OF POST-TRIAL BRIEFING SCHEDULE
`
`Plaintiff Seagen Inc. (“Seagen”) filed a notice with the Court on May 4, 2022 stating that
`
`“Seagen’s Motion for Entry of Post-Trial Briefing Schedule (Dkt. No. 390) is ripe for decision.”
`
`Dkt. 397. Seagen’s position that its motion for entry is ripe for decision is inconsistent with the
`
`Court’s order of April 28, 2022, which granted Defendants Daiichi Sankyo Company, Limited,
`
`AstraZeneca Pharmaceuticals LP, and AstraZeneca UK Ltd.’s (collectively, “Defendants”)
`
`Motion for Expedited Briefing on its Motion to Stay Pending Post-Grant Review in order to
`
`“facilitate the Court’s simultaneous review of the parties’ outstanding motions.” Dkt. 395.
`
`Defendants will be filing a reply in support of its motion to stay on Wednesday, May 11, 2022,
`
`after which time, barring any further sur-reply from Seagen, both motions will be ready for the
`
`Court’s simultaneous review.
`
`
`
`Case 2:20-cv-00337-JRG Document 400 Filed 05/09/22 Page 2 of 4 PageID #: 15544
`
`Dated: May 9, 2022
`
`
`Respectfully submitted,
`
` /s/ Preston K. Ratliff II
`
`Deron R. Dacus
`State Bar No. 00790553
`The Dacus Firm, P.C.
`821 ESE Loop 323, Suite 430
`Tyler, Texas, 75701
`+1 (903) 705-1117
`+1 (903) 581-2543 facsimile
`ddacus@dacusfirm.com
`
`J. Mark Mann
`State Bar No. 12926150
`mark@themannfirm.com
`MANN | TINDEL | THOMPSON
`300 West Main Street
`Henderson, Texas 75652
`(903) 657-8540
`(903) 657-6003 (fax)
`
`Attorneys for Defendant Daiichi Sankyo Company,
`Limited
`
`Of Counsel:
`
`Preston K. Ratliff II
`Ashley N. Mays-Williams
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`(212) 318-6000
`
`Jeffrey A. Pade
`Paul Hastings LLP
`2050 M Street NW
`Washington, DC 20036
`(202) 551-1700
`
`Attorneys for Defendant Daiichi Sankyo Company,
`Limited
`
`
`
`
`
`-2-
`
`
`
`Case 2:20-cv-00337-JRG Document 400 Filed 05/09/22 Page 3 of 4 PageID #: 15545
`
` /s/ David Berl
`
`Jennifer Parker Ainsworth
`Texas State Bar No. 00784720
`WILSON, ROBERTSON & CORNELIUS, P.C.
`909 ESE Loop 323, Suite 400
`Tyler, Texas 75701
`Phone: (903) 509-5000
`Facsimile: (903) 509-5092
`
`Attorneys for Intervenor-Defendants AstraZeneca
`Pharmaceuticals LP and AstraZeneca UK Ltd
`
`Of Counsel:
`
`David I. Berl
`Thomas S. Fletcher
`Jessamyn Berniker
`Jessica L. Pahl
`Kathryn Kayali
`Kevin Hoagland-Hanson
`Angela X. Gao
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`Phone: (202) 434-5000
`Facsimile: (202) 434-5029
`
`Attorneys for Intervenor-Defendants AstraZeneca
`Pharmaceuticals LP and AstraZeneca UK Ltd
`
`-3-
`
`
`
`
`
`
`
`
`
`Case 2:20-cv-00337-JRG Document 400 Filed 05/09/22 Page 4 of 4 PageID #: 15546
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that all counsel of record who have consented to
`
`electronic service are being served with a copy of this document via electronic mail on May 9,
`
`2022.
`
`/s/ Preston K. Ratliff II
`
`